EB-203 / EyebioKorea - LARVOL DELTA

Determination of Human Effective Dose via Translational Ocular Modeling: Clinical Translation of a Novel Topical Agent Using PBPK. (PubMed, Clin Transl Sci) - "This PBPK framework provides a practical approach for predicting human ocular drug exposure and can be adapted to other compounds or ocular indications in the absence of direct tissue sampling. These results support further clinical evaluation of EB-203 for the treatment of wAMD."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Evaluation of EB-203 as a potential treatment for non-proliferative diabetic retinopathy using a zebrafish model. (PubMed, Biomed Pharmacother) - "EB-203 was found to reduce microvascular leakage changes, edema features, and inflammatory responses associated with NPDR-like phenotypes, suggesting its potential to limit progression toward PDR conditions. Overall, EB-203 demonstrated significant efficacy in improving NPDR like retinal pathology in zebrafish and holds promise as a potential therapeutic candidate for DR."

Journal • Diabetes • Diabetic Retinopathy • Inflammation • Retinal Disorders

EB-203-201: Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: EyebioKorea, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

EB-203-201: Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - P2 | N=50 | Not yet recruiting | Sponsor: EyebioKorea, Inc.

New P2 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: EyebioKorea, Inc. | Recruiting ➔ Completed | Trial completion date: May 2023 ➔ Oct 2022

Trial completion • Trial completion date

Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers (clinicaltrials.gov) - P1 | N=28 | Recruiting | Sponsor: EyebioKorea, Inc.

New P1 trial